Original Articles
Reports of original investigations in refereed journals.
1.
2.
3.
4.
5.
6.
Nielsen S, Miravalle A, Langer-Gould A, Cooper J, Edwards K, Kinkel P. B cell
depletion and safety of low dose rituximab in patients with relapsing multiple
sclerosis. Mult Scler 2012; 18: 377-378.
Edwards K, Goodman W. Improvement of neuropsychological function in cognitively
impaired multiple sclerosis treated with natalizumab. Int. J MS Care 2012; 14:100104
Edwards K, Rosenthal B, Farmer K et all. Evaluation of Sumatriptan-Naproxen in the
treatment of acute migraine headache. Headache 2012; 53:656-664
Edwards K, Cadavid D, Ranger A et all. Feasibility study of the Use of Combinatorial
Chemokine Arrays to study blood and CSF in MS. PLoS One 2013, 8:e81007
Fox E, Edwards K, Burch JG, Wynn D et al Outcomes of Switching Directly to Oral
Fingolimod from Injectable Therapies: Results of the Evaluate Patient OutComes
(EPOC) Study in Relapsing Multiple Sclerosis. In Press Mult Sclerosis and Related
Disorders
Edwards K, Cree B, Crayton H, Kantor D, et al. Change from baseline in PROs
(TSQM, FSS, BDI-II) and CGI-I in previously treated Interferon and glatiramer
patients switching to Gilenya vs staying on interferons or glatiramer. In preparation
Calkwood J, Cree B, Edwards K et al Impact of a switch to fingolimod versus staying
on glatiramer acetate or beta interferons on patient- and physician-reported outcomes
in relapsing MS: post hoc analysis of the EPOC trial. In press
Proceedings of Meetings
Published full length articles of meeting presentations for which papers were selected
and which contain new data.
Poster and Platform Presentations, National and International Meetings: (2011Present)
1.
2.
3.
4.
February 15-20, 2011 “The level of CXCL13 correlates with a B cell and plasma cell
transcription signature in the cerebrospinal fluid of secondary progressive multiple
sclerosis patients”. (Platform Presentation). Presented at the Keystone Symposia on
Molecular and Cellular Biology in Taos, New Mexico.
April 9-April 16, 2011 “Evaluation of Sumatriptan-Naproxen in the Treatment of Acute
Migraine Headache: A Placebo Controlled, Double Blind, Crossover Study accessing
Cognitive Function”. (Poster Presentation). Presented at the 63rd American Academy of
Neurology (AAN) in Honolulu, Hawaii.
April 9-April 16, 2011 “Capture of Patient-Perceived Negative Mood Traits to Omprove
Treatment for Patients with Multiple Sclerosis”. (Poster Presentation). Presented at the
63rd American Academy of Neurology (AAN) in Honolulu, Hawaii
April 9-April 16, 2011 “Decrease in Individual Multiple Sclerosis Severity scores during
follow-up Period: Analysis of the New York State Multiple Sclerosis Consortium
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Dataset”. (Poster Presentation). Presented at the 63rd American Academy of Neurology
(AAN) in Honolulu, Hawaii
April 9-April 16, 2011 “Pregnancy related to disability outcomes for women with
progressive multiple sclerosis”. (Poster Presentation). Presented at the 63rd American
Academy of Neurology (AAN) in Honolulu, Hawaii
April 13, 2011 “CSF levels of secondary lymphoid organ chemokines are elevated in
relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis and
worsen during acute exacerbations” (Platform Presentation). Presented at the 63rd
American Academy of Neurology (AAN) in Honolulu, Hawaii
June 2-5, 2011 “Cognitive Dysfunction at Onset of Acute Migraine” Presented at the 53rd
Annual Scientific Meeting for the American Headache Society Washington, DC.
June 2-5, 2011 “An Evaluation of Sumatriptan-Naproxen (Treximet) in the treatment of
Acute Migraine Headache: A Placebo controlled, double blind, crossover study accessing
cognitive function.” Presented at the 53rd Annual Scientific Meeting for the American
Headache Society Washington, DC.
April 21-April 28, 2012 “Natalizumab use for neuropsychological deficits in relapsing
multiple sclerosis”. (Poster Presentation). Presented at the 64th American Academy of
Neurology (AAN) in New Orleans, LA.
May 29 -June 1, 2013 “Treatment satisfaction and clinical improvement after switch to
fingolimod”. (Poster Presentation). Presented at the 27th Annual Meeting of the CMSC
and the 5 th Cooperative Meeting of CMSC-ACTRIMS, Orlando, Florida
June 8-11, 2013 “Treatment satisfaction and clinical improvement after switch to
fingolimod”. (Poster Presentation). Presented at the 23rd Meeting of the European
Neurological Society in Barcelona, Spain
October 2-5, 2013 “Patient- and physician-reported outcomes after therapy switch from
interferon beta to fingolimod versus staying on interferon beta therapy” (Poster
Presentation) - Accepted at the 29th congress of the European Committee for Treatment
and Research in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of
rehabilitation in MS (RIMS), Copenhagen, Denmark
April 26 – May 3, 2014 “ Safety of Using Disease-modifying Therapy Postalemtuzumab Treatment in Patients with Relapsing-remitting Multiple Sclerosis in the
Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II studies”
(Poster Session II) Accepted at the American Academy of Neurology 66th Annual
Meeting in Philadelphia, PA
April 26- May 3, 2014 “ Treatment Satisfaction after Switching to Fingolimod directly
from an injectable therapy” (Poster Session VII) Accepted at the American Academy of
Neurology 66th Annual Meeting in Philadelphia, PA
May 28-June2, 2014 “Switching from Natalizumab to Teriflunomide in Multiple
Sclerosis Patients Who Have Received Natalizumab for More Than 12 Months” (Poster
session ) Accepted at the 6th Cooperative Meeting of CMSC-ACTRIMS, Dallas, Tx
May 28-June 2, 2014 “Patient and Physician Reported Outcomes after Therapy Switch
from Interferons or Glatiramer Acetate to Fingolimod” (Poster session ) Accepted at the
6th Cooperative Meeting of CMSC-ACTRIMS, Dallas, Tx
September 10-13, 2014 “Teri-Pro: Study Design and US Patients Baseline
Characteristics” - Accepted at the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS), Boston, MA